Market Research Logo

Vulvovaginal Candidiasis - Pipeline Review, H1 2015


Attention: There is an updated edition available for this report.

Vulvovaginal Candidiasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Vulvovaginal Candidiasis - Pipeline Review, H1 2015’, provides an overview of the Vulvovaginal Candidiasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vulvovaginal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Vulvovaginal Candidiasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Vulvovaginal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Vulvovaginal Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Vulvovaginal Candidiasis Overview
Therapeutics Development
Pipeline Products for Vulvovaginal Candidiasis - Overview
Pipeline Products for Vulvovaginal Candidiasis - Comparative Analysis
Vulvovaginal Candidiasis - Therapeutics under Development by Companies
Vulvovaginal Candidiasis - Pipeline Products Glance
Clinical Stage Products
Vulvovaginal Candidiasis - Products under Development by Companies
Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development
Actavis plc
Grupo Ferrer Internacional, S.A.
NovaDigm Therapeutics, Inc.
Viamet Pharmaceuticals, Inc.
Vulvovaginal Candidiasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
albaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arasertaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NDV-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NDV-3A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEV-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vulvovaginal Candidiasis - Recent Pipeline Updates
Vulvovaginal Candidiasis - Dormant Projects
Vulvovaginal Candidiasis - Discontinued Products
Vulvovaginal Candidiasis - Product Development Milestones
Featured News & Press Releases
Sep 10, 2014: Data for Viamet’s VT-1161 Presented at ICAAC 2014
Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis
Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161
Sep 24, 2013: Viamet Pharmaceuticals Expands Phase 2 Clinical Program with Novel Antifungal Agent VT-1161
Sep 05, 2013: Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-1161
Aug 08, 2012: Ferrer Submits IND For Arasertaconazole Nitrate For Vulvovaginal Candidiasis
Jan 17, 2012: Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory In All Vaccinees
Oct 11, 2011: Pevion’s Therapeutic Candida Vaccine PEV7 Shows Robust Systemic And Mucosal Immunogenicity
Sep 01, 2011: Pevion Grants CSL Option Right To Therapeutic Candida Vaccine
Nov 11, 2010: Pevion Announces Positive Preliminary Results From Phase I Study Of PEV7 In Recurrent Vulvovaginal Candidiasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Vulvovaginal Candidiasis, H1 2015
Number of Products under Development for Vulvovaginal Candidiasis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Products under Development by Companies, H1 2015
Vulvovaginal Candidiasis - Pipeline by Actavis plc, H1 2015
Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015
Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H1 2015
Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Vulvovaginal Candidiasis Therapeutics - Recent Pipeline Updates, H1 2015
Vulvovaginal Candidiasis - Dormant Projects, H1 2015
Vulvovaginal Candidiasis - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Vulvovaginal Candidiasis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report